Precision therapy versus standard therapy in Acute Myeloid Leukaemia and Myelodysplastic syndrome in elderly (PALM) – a phase II randomized clinical trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509092-16-00

Acronym

PALM

Enrollment

Registered

2024-10-18

Start date

Unknown

Completion date

2025-11-27

Last updated

2024-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic myelomonocyte leukemia, Myelodysplastic syndrome, Acute myeloid leukemia

Brief summary

Cost-effectiveness of precison therapy, defined by the incremental costs per quality adjusted life-years gained (QALYs) based on measurements of Health-related quality of life (HRQoL) and total costs of treatment and follow-up

Interventions

DRUGDacogen 50 mg powder for concentrate for solution for infusion.

DRUGNexavar 200 mg film-coated tablets

DRUGVepesid 50 mg kapsler

DRUGmyke

DRUGVenclyxto 50 mg film-coated tablets

DRUGTafinlar 75 mg hard capsules

DRUGMekinist 2 mg film-coated tablets

DRUGAtorvastatin Accord 10 mg filmdrasjerte tabletter

DRUGVidaza 25 mg/ml powder for suspension for injection

DRUGHydroxyurea medac 500 mg kapsel

DRUGhard

DRUGVenclyxto 100 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Cost-effectiveness of precison therapy, defined by the incremental costs per quality adjusted life-years gained (QALYs) based on measurements of Health-related quality of life (HRQoL) and total costs of treatment and follow-up	—

Countries

Norway

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026